First-in-human randomized clinical trials of the safety and efficacy of tanezumab for treatment of chronic knee osteoarthritis pain or acute bunionectomy pain.

about

First-in-human randomized clinical trials of the safety and efficacy of tanezumab for treatment of chronic knee osteoarthritis pain or acute bunionectomy pain.

Item

http://www.wikidata.org/entity/Q55264146

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

First-in-human randomized clin ...... in or acute bunionectomy pain.

@en

First-in-human randomized clin ...... in or acute bunionectomy pain.

@nl

type

Item

label

First-in-human randomized clin ...... in or acute bunionectomy pain.

@en

First-in-human randomized clin ...... in or acute bunionectomy pain.

@nl

prefLabel

First-in-human randomized clin ...... in or acute bunionectomy pain.

@en

First-in-human randomized clin ...... in or acute bunionectomy pain.

@nl

P1476

First-in-human randomized clin ...... in or acute bunionectomy pain.

@en

P2093

Christine R West

http://www.w3.org/2001/XMLSchema#string

David L Shelton

http://www.w3.org/2001/XMLSchema#string

Franz Hefti

http://www.w3.org/2001/XMLSchema#string

Jon L Ruckle

http://www.w3.org/2001/XMLSchema#string

Mark T Brown

http://www.w3.org/2001/XMLSchema#string

Patricia A Walicke

http://www.w3.org/2001/XMLSchema#string

Roxanne Bales

http://www.w3.org/2001/XMLSchema#string

Shiao-Ping Lu

http://www.w3.org/2001/XMLSchema#string

P2860

Non-steroidal anti-inflammatory drugs for low back pain

Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee

Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines.

OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines.

Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain.

Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial.

Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society.

Antagonism of nerve growth factor-TrkA signaling and the relief of pain

Novel class of pain drugs based on antagonism of NGF.

Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain.

P304

e653

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/PR9.0000000000000653

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29922745

http://www.w3.org/2001/XMLSchema#string

P921

chronic pain

P932

5999411

http://www.w3.org/2001/XMLSchema#string